公开(公告)号：WO2018006171A1

公开(公告)日：2018-01-11

申请号：PCT/CA2017/050812

申请日：2017-07-05

Applicant: UNIVERSITY OF SASKATCHEWAN ,  SASKATCHEWAN CANCER AGENCY

Inventor： VIZEACOUMAR, Franco Joseph ,  FREYWALD, Andrew ,  PAUL, James Mathew ,  VIZEACOUMAR, Frederick Sagayaraj

IPC: C12Q1/68 ,  A61P35/00 ,  C12Q1/02 ,  C40B30/06 ,  G01N33/15 ,  G01N33/48 ,  A61K31/00

Abstract: Methods for identifying a subject with a cancer eligible for treatment with an inhibitor of a Table 1 molecule, optionally a SRC kinase inhibitor or a MET kinase inhibitor, are provided. The methods comprise testing a biological sample from the subject for a deficiency in EPHB6 receptor levels, wherein the subject is eligible for treatment with an inhibitor of a Table 1 molecule, optionally a SRC kinase inhibitor or a MET kinase inhibitor, if EPHB6 receptor levels in the biological sample are deficient.

Abstract translation: 提供了用于鉴定具有适合用表1分子的抑制剂，任选的SRC激酶抑制剂或MET激酶抑制剂治疗的癌症的受试者的方法。 该方法包括测试来自受试者的生物样品中EPHB6受体水平的缺乏，其中该受试者适合用表1分子的抑制剂，任选的SRC激酶抑制剂或MET激酶抑制剂治疗，如果EPHB6受体水平 生物样本不足。